Journal
HEALTH POLICY
Volume 121, Issue 7, Pages 745-754Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.healthpol.2017.05.005
Keywords
Public-private partnerships; Neglected tropical diseases; Health economics; Public health; Research and development
Funding
- European Union's Horizon research and innovation program under the Marie Sklodowska-Curie grant [642609]
Ask authors/readers for more resources
Pharmaceutical companies are reluctant to invest in research and development (R&D) of products for neglected tropical diseases (NTDs) mainly due to the low ability-to-pay of health insurance systems and of potential consumers. The available preventive and curative interventions for NTDs mostly rely on old technologies and products that are often not adequate. Moreover, NTDs mostly affect populations living in remote rural areas and conflict zones, thereby hampering access to healthcare. The challenges posed by NTDs have led to the proliferation of a variety of public-private partnerships (PPPs) in the last decades. We conducted a systematic review to assess the functioning and impact of these partnerships on the development of and access to better technologies for NTDs. Our systematic review revealed a clear lack of empirical assessment of PPP5: we could not find any impact evaluation analyses, while these are crucial to realize the full potential of PPP5 and to progress further towards NTDs elimination. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available